

## Formulation and Evaluation of Floating Microspheres of Rabeprazole Sodium

Yash Paul\* and Reetika Dadial

Lord Shiva College of Pharmacy, Sirsa-125055 (Haryana) India

### ABSTRACT

The aim of current research was to prepare and evaluate the floating microspheres of Rabeprazole sodium to prolonging its gastric retention time. Rabeprazole sodium is a proton pump inhibitor which acts by suppressing gastric  $H^+$ ,  $K^+$  ATPase at the secretory surface of the gastric parietal cells. It has poor oral bioavailability (52%) and short half life (1-2h) owing to its poor absorption in the lower git tract. The floating microspheres of Rabeprazole sodium were prepared by emulsion solvent diffusion method using Eudragit RS 100 and HPMC K4M as polymers and using dichloromethane and ethanol as a solvent system. The prepared microspheres were evaluated for micromeretic properties, percentage yield, particle size, percentage yield, entrapment efficiency, *in-vitro* floating efficiency and *in-vitro* drug release studies. The prepared microsphere were found to be spherical and free flowing and remain buoyant for more than 8 h and percentage yield was found to be in the range 86.95% to 66.03%. The drug entrapment efficiency was found to be 90.12% to 59.87%, particle size in the range of 208 $\mu$ m to 550 $\mu$ m. *In-vitro* release studies showed that drug is released from the formulation over period of 12h in a sustained manner and the release mechanism followed a fickian type.

**KEYWORDS:** Microspheres, Rabeprazole sodium, emulsion Solvent diffusion method, Eudragit RS 100, HPMC K4M.

### \* Corresponding Author

Dr. Yash Paul Singla  
Professor & Principal  
Lord Shiva College of Pharmacy  
Sirsa-125055 (Haryana) India  
Phone: +91-1666-329204(O); 232684(R); Fax 242695 (O)  
E-mail: [ypsingla@yahoo.co.in](mailto:ypsingla@yahoo.co.in)

## **INTROUCTION:**

Oral drug delivery has been known for decades as the most widely utilized route for administering drugs among all the routes that have been employed for the systemic delivery of drugs *via* various pharmaceutical products of different dosage forms. The reasons that the oral route achieved such popularity may be in part attributed to its ease of administration without any expertise assistance, patient compliance, flexibility in formulation.<sup>1</sup> Gastroretentive drug delivery system (GRDDS) is one of the novel approach in this area. Drugs that are easily absorbed from gastrointestinal tract (GIT) and have short half-lives are eliminated quickly from the systemic circulation. Frequent dosing of these drugs is required to achieve suitable therapeutic activity. To avoid this limitation, the development of oral sustained-controlled release formulations is an attempt to release the drug slowly into the GIT and maintain an effective drug concentration in the systemic circulation for a long time. After oral administration, such a drug delivery would be retained in the stomach and release the drug in a controlled manner, so that the drug could be supplied continuously to its absorption sites in the GIT.<sup>2</sup>

The controlled gastric retention of solid dosage forms may be achieved by the mechanisms of mucoadhesion, floatation, sedimentation, expansion modified shape systems, or by the simultaneous administration of pharmacological agent.<sup>3</sup> Floating systems was firstly developed by Davis in 1968. Floating drug delivery system is an effective technology to prolong the gastric residence time in order to improve the bioavailability of the drug. Floating drug delivery systems have a bulk density less than gastric fluids and so remain buoyant in the stomach without affecting gastric emptying rate for a prolonged period of time.<sup>4</sup>

Microspheres can be defined as solid, approximately spherical particles ranging in size from 1 to 1000 micrometer. The Microspheres are characteristically free flowing powders consisting of proteins or synthetic polymers, which are biodegradable in nature. Solid biodegradable microspheres incorporating a drug dispersed or dissolved throughout particle matrix have the potential for controlled release of drugs.<sup>5</sup> Gastro-retentive floating microspheres are low-density systems that have sufficient buoyancy to float over gastric contents and remain in stomach for prolonged period. As the system floats over gastric contents, the drug is released slowly at desired rate resulting in increased gastric retention with reduced fluctuations in plasma drug concentration.<sup>6</sup>

The objective of current study was to formulate and evaluate of floating microspheres of rabeprazole sodium. Rabeprazole sodium was chosen as a drug candidate for floating microspheres

formulation owing to its poor oral bioavailability (52%) and short half life (1-2h) because it is poorly absorbed in lower GI tracts. Rabepazole sodium is a benzimidazole derivative and potent anti-ulcer agent.<sup>7,8</sup> Moreover, rabepazole sodium belongs to BCS class III and hence possesses high aqueous solubility and low permeability. To improve the oral bioavailability and half life of drug floating microspheres were prepared using rate controlling polymer Eudragit RS 100 and hydrophilic polymer HPMC K4M by emulsion solvent diffusion techniques.

## **EXPERIMENTAL**

### ***Materials***

Pure Rabepazole sodium was obtained from Alkem laboratory Ltd. Mumbai exgratis, The other chemicals were obtained from authenticated manufacturers i.e Eudragit RS 100 (Leo chem. Bangalore, Karnataka), Hydroxy methyl cellulose (Leo Chem. Mumbai), Ethanol (Nice Chemicals Pvt. Ltd, Cochin, Kerala), Dichloromethane (Ranbaxy fine chemical. Ltd, New Delhi, India), Polyvinylalcohol (Ranbaxy fine chemical. Ltd, New Delhi). All other reagents used were of analytical grade.

### ***Method of Preparation of Floating Microspheres***

Floating microspheres having rabepazole sodium (60 mg) were prepared using emulsion solvent diffusion technique. Nine different formulations (F1 to F9) were prepared using a polymer mixture of Eudragit RS100, Hydroxypropylmethylcellulose (HPMC K4M). After number of initial trials Eudragit RS100 concentration was fixed to 400 mg in each formulation where as concentration of HPMC K4M was varied from 0-80 mg as show in table 1. In each formulation the drug polymer mixture was dissolved in a blend of ethanol (8mL) and dichloromethane (8mL). The resultant mixture was dropped into 0.75% polyvinyl alcohol solution (200mL). The solution was stirred with a propeller type agitator at 40°C temperature for 1h at 300 rpm. The formed floating microspheres were passed through Sieve no- 12, washed with water and dried at room temperature using desiccators

### ***Evaluation of Floating Microspheres***

The prepared floating microspheres of rabepazole sodium were evaluated for their quality control tests like micromeretics studies, percentage yield, drug entrapment efficiency, particle size and shape analysis, FTIR studies, scanning electron microscopy, *In-vitro* buoyancy, *In-vitro* drug release studies etc.

**Table No. 1: Composition of various formulations of floating microspheres containing Rabeprazole sodium**

| Formulation code | Drug (mg) | Polymer ratio (mg) |          | Organic solvent ratio (1:1mL) |                 |
|------------------|-----------|--------------------|----------|-------------------------------|-----------------|
|                  |           | Eudragit RS 100    | HPMC K4M | Ethanol                       | Dichloromethane |
| F1               | 60        | 400                | -        | 8                             | 8               |
| F2               | 60        | 400                | 10       | 8                             | 8               |
| F3               | 60        | 400                | 20       | 8                             | 8               |
| F4               | 60        | 400                | 30       | 8                             | 8               |
| F5               | 60        | 400                | 40       | 8                             | 8               |
| F6               | 60        | 400                | 50       | 8                             | 8               |
| F7               | 60        | 400                | 60       | 8                             | 8               |
| F8               | 60        | 400                | 70       | 8                             | 8               |
| F9               | 60        | 400                | 80       | 8                             | 8               |

## MICROMERETICS STUDIES<sup>9</sup>

The following micromeretic properties were studied for the developed floating microspheres of rabeprazole sodium.

### *Bulk Density/ Tapped Density*

Both bulk density (BD) and tapped density (TD) were determined. A suitable amount of microspheres from each formulation, was introduced into a 100 mL measuring cylinder. After observing its initial volume, the cylinder in the density tapper instrument and density is measured according to USP method II (up to 1250 taps). The tapping was continued until no further change in volume was noted. Volume of packing after tapping was noted. BD and TD were calculated using eqn. 1 and 2 respectively.

$$\text{BD} = \text{weight of the powder} / \text{volume of the packing} \quad \dots(1)$$

$$\text{TD} = \text{weight of the powder} / \text{tapped volume of packing} \quad \dots(2)$$

### *Compressibility Index*

Compressibility index of the microspheres was determined by Carr's compressibility index as given by eqn. 3 and inference was drawn on the basis of values of % compressibility shown in table 15.<sup>10,11</sup>

$$\text{Carr's index (\%)} = [(\text{TD} - \text{BD}) \times 100] / \text{TD} \quad \dots(3)$$

### ***Angle of Repose***

Static angle of repose was measured according to the fixed funnel and free standing core method of Banker and Anderson. Microspheres were carefully poured through the funnel until the apex of the conical pile so formed just reached the tip of the funnel. Height of instrument was fixed to 4 cm. Thus, with r being the radius of the base of the microspheres conical pile and the angle of repose ( $\theta$ ) was calculated by using the eqn. 4.<sup>10,11</sup>

$$\tan \theta = h/r \quad \dots(4)$$

### ***Hausner's Ratio***

It is the ratio of tapped to bulk density and was calculated by using the eqn. 6.<sup>12</sup>

$$\text{Hausner's ratio} = \text{TD/BD} \quad \dots(5)$$

### ***Percentage Yield***

The prepared microspheres were collected and weighed. The measured weight was divided by the total amount of all non-volatile components, which were used for the preparation of the microspheres. The percentage yield of floating microspheres was calculated using eqn.6<sup>13</sup>

$$\% \text{ Yield} = (\text{Actual weight of product} / \text{Total Weight of excipient and drug}) \times 100 \quad \dots(6)$$

### ***Drug Entrapment Efficiency***

To determine the incorporation efficiency, microspheres were taken, thoroughly triturated and suspended in a minimal amount of alcohol. The suspension was suitably diluted with water and filtered to separate shell fragments. Drug content was analyzed spectrophotometrically at 260.5 nm. The drug entrapment efficiency of floating microspheres was calculated using eqn. 7<sup>13</sup>

$$\text{Drug entrapment efficiency (\%)} = \text{Actual drug content} \times 100 / \text{Theoretical drug content} \quad \dots(7)$$

### ***Particle Size and Shape***

The particle size of the microspheres was measured using an optical microscopic method and the mean particle size was calculated by measuring 25 particles with the help of a calibrated ocular micrometer with stage micrometer<sup>9</sup>

### ***Fourier Transform Infrared Spectroscopy Studies***

The drug - polymer interaction and also degradation of drug while processing for microspheres was determined by Fourier Transform Infra-Red (FTIR) spectroscopy studies. The FT-IR spectra of the samples were recorded in the KBr disk using IR Spectrophotometer.

### ***Scanning Electron Microscopy Studies***

The external and internal morphology of the microspheres were studied using Scanning Electron Microscopy (SEM). The samples for SEM were prepared by lightly sprinkling on a double adhesive tape stuck to an aluminum stub. The stubs were then coated with platinum to a thickness of about 10 Å under an argon atmosphere using a gold sputter module in a high vacuum evaporator. The stub containing the coated samples was placed in the scanning electron microscope (JSM- 6360A; JEOL, Tokyo, Japan) chamber. The samples were then randomly scanned, and photomicrographs were taken at the acceleration voltage of 20 kV.<sup>14</sup>

### ***In-Vitro Floating Efficiency***

Fifty milligrams of the floating multiparticulates were placed in 100 mL of the simulated gastric fluid (SGF, pH 2.0) containing 0.02% w/v Tween 20. The mixture was stirred at 100 rpm with a magnetic stirrer. After 8 hours, the layer of buoyant multiparticulate was pipetted and separated by filtration. Particles in the sinking particulate layer were separated by filtration. Particles of both types were dried in a desiccator until constant weight was achieved. Both the fractions of microspheres were weighed and buoyancy was determined by the weight ratio of floating particles to the sum of floating and sinking particles. The floating efficiency of floating microsphere can be calculated by eqn. 8

$$\text{Buoyancy (\%)} = (W_f / W_f + W_s) \times 100 \quad \dots(8)$$

Where,  $W_f$  and  $W_s$  are the weights of the floating and settled microparticles.<sup>9</sup>

### ***In-Vitro Drug Release Studies***

Release rate of drug from hollow floating microspheres was determined using USP dissolution apparatus type II at  $37 \pm 0.5^\circ\text{C}$ . The dissolution test was carried out using 900 mL of 0.1 N HCl dissolution medium at 100 rpm for the required period of time. At an appropriate interval, specific volume of aliquots were withdrawn and replaced with an equivalent volume of fresh dissolution medium to maintain the constant volume of dissolution medium. The sample solutions were filtered through Whatman filter paper and solutions were analysed using UV spectrophotometer.

### ***Kinetic Analysis of Dissolution Data***

The dissolution data of floating microspheres of rabeprazole sodium of optimized formulation F6 was fitted to zero order, first order, Higuchi's and Korsmeyer-Peppas model to ascertain the kinetic modeling of drug release.

## **RESULTS AND DISSCUSION**

All the nine floating microspheres formulations of rabeprazole sodium were evaluated in terms of floating parameters.

### ***Micromeretics Studies***

Micromeritic properties of the prepared microspheres of various formulations F1 to F9 were evaluated for bulk density, tapped density, Carr's index, angle of repose and hausner's ratio. BD and TD for all the formulations were found in the range between 0.375 to 0.750 and 0.432 to 0.750 respectively. Compressibility index of the microspheres of various formulations was found in the range of 6.28% to 13.19%. These values indicate the excellent flow properties. Because in the range of 5-15% carr's index shows excellent flow respectively. The angle of repose of the floating microspheres of various formulations was in the range  $22.98^{\circ}$  to  $27.35^{\circ}$ , indicating that the studied floating microspheres have good to excellent flow properties, because  $\theta$  should be  $25^{\circ}$ - $30^{\circ}$  and  $<25^{\circ}$  shows good flow properties respectively. The hausner's ratio of the floating microspheres of various formulations was in the range 1.06 to 1.15 indicating that the studied floating microspheres have good flow rate. Because the range of hausner's ratio less than 1.25 shows good flow. The results suggest that all the values are within the range, which indicates good flow properties the values were given in table 2.

**Table-2 Micromeritics studies of floating microspheres of rabeprazole sodium**

| Formulation code | Bulk density (gm/cm) | Tapped density (gm/cm) | Carr's index (%) | Angle of repose | Hauner's ratio |
|------------------|----------------------|------------------------|------------------|-----------------|----------------|
| F1               | 0.462                | 0.493                  | 6.28             | 27.35           | 1.06           |
| F2               | 0.461                | 0.500                  | 7.80             | 25.70           | 1.08           |
| F3               | 0.666                | 0.750                  | 11.20            | 26.56           | 1.12           |
| F4               | 0.385                | 0.421                  | 8.50             | 25.76           | 1.09           |
| F5               | 0.625                | 0.689                  | 9.28             | 24.31           | 1.102          |
| F6               | 0.461                | 0.530                  | 13.01            | 24.91           | 1.14           |
| F7               | 0.500                | 0.542                  | 7.74             | 22.98           | 1.08           |
| F8               | 0.468                | 0.500                  | 6.40             | 25.82           | 1.06           |
| F9               | 0.375                | 0.432                  | 13.19            | 25.11           | 1.15           |

### **Percentage Yield**

The percentage yield of produced floating microspheres of rabeprazole sodium of various formulations F1 to F9 was found to be in the range of 86.95% to 66.03% as shown in table 3.

**Table-3: Evaluation parameters of floating microspheres of rabeprazole Na of various formulations F1 to F9.**

| Formulation code | Percentage yield | Drug entrapment efficiency | Particle size ( $\mu\text{m}$ ) | Shape of microspheres | Percent buoyancy after 8h |
|------------------|------------------|----------------------------|---------------------------------|-----------------------|---------------------------|
| F1               | 86.95 $\pm$ 0.85 | 90.12 $\pm$ 0.53           | 550 $\pm$ 1.15                  | Spherical             | 90 $\pm$ 0.06             |
| F2               | 82.97 $\pm$ 0.15 | 84.6 $\pm$ 3.02            | 450 $\pm$ 0.09                  | Spherical             | 87 $\pm$ 0.12             |
| F3               | 78.53 $\pm$ 0.14 | 81.63 $\pm$ 2.02           | 420 $\pm$ 0.55                  | Spherical             | 89 $\pm$ 0.16             |
| F4               | 76.47 $\pm$ 0.96 | 78.73 $\pm$ 2.00           | 384 $\pm$ 0.63                  | Spherical             | 82 $\pm$ 1.09             |
| F5               | 70.63 $\pm$ 2.81 | 76.48 $\pm$ 2.14           | 337 $\pm$ 2.23                  | Spherical             | 77 $\pm$ 0.03             |
| F6               | 68.56 $\pm$ 1.23 | 73.01 $\pm$ 2.81           | 312 $\pm$ 2.56                  | Spherical             | 75 $\pm$ 0.20             |
| F7               | 67.31 $\pm$ 3.81 | 68.46 $\pm$ 1.07           | 280 $\pm$ 1.08                  | Spherical             | 73 $\pm$ 1.32             |
| F8               | 66.03 $\pm$ 1.53 | 63.29 $\pm$ 0.98           | 246 $\pm$ 3.21                  | Spherical             | 69 $\pm$ 0.56             |
| F9               | 64.79 $\pm$ 2.38 | 59.87 $\pm$ 1.58           | 208 $\pm$ 1.78                  | Spherical             | 64 $\pm$ 2.45             |



It has been observed that percentage yield decrease F2 to F9. However, low percentage yield in some formulation may be because of microspheres lost during successive decantation during washing process. Parallel trend was observed in case of floating microspheres of metformin HCL.<sup>15</sup>

### ***Drug Entrapment Efficiency***

The formulation containing drug : HPMC K4M : Eudragit RS 100 ratio, The drug entrapment efficiencies of different formulations were in the range of 90.12% to 59.87 is shown in table 3. It indicating that the drug entrapment efficiency slightly decrease with increase in the concentration of HPMC K4M.

### ***Particle Size and Shape***

The particle size and shape of the microspheres was measured using optical microscope. The particle size of the floating microspheres of rabeprazole sodium of various formulations was found to be in the range of 208µm to 550µm and spherical it is shown in table 3. It was observed that the mean particle size of the floating microspheres was significantly decreased with increased in the concentration of HPMC K4M and with the concentration of Eudragit RS 100 the particle size increased.

### ***Fourier- Transform Infrared Spectroscopy Studies***

The rabeprazole sodium along with the physical mixture of Eudragit RS 100 and HPMC K4M was kept at different environment condition to observe the physical compatibility of the drug with excipient. A comparison of the initial sample, control sample and the samples kept at different environmental condition for physical changes was visually done periodically at different times. No physical changes were observed with respect to colour, odour, lump formation etc. The result obtained from Physical compatibility studies were confirmed by FT-IR studies (Fig. 1, 2). Compares FT-IR spectra of pure drug and its mixture with Eudragit RS 100 and HPMC K4M

On comparing the above two spectra it is evident that all the peaks of rabeprazole sodium were present in the sample (Drug + Excipient) kept under compatibility studies. Therefore, it can be concluded that there was no physical and chemical changes occurred indicating that excipients are compatible with the drug.




Fig.1: FT-IR spectra of pure drug





Fig.2: FT-IR spectra of Drug + excipients

## SCANNING ELECTRON MICROSCOPY

Morphology of floating microspheres of F6 formulation was examined by scanning electron microscope. The view of the microspheres showed hollow structure with a smooth surface morphology (fig. 3). It is also evident from fig 3 that the outer shell of microspheres is porous. The porous shell was obtained may be due to evaporation of solvent entrapped within the shell of microsphere.



**Fig.3: SEM of floating microspheres of Rabepazole sodium**

### ***IN-VITRO* FLOATING EFFICIENCY**

The *in-vitro* floating efficiency of floating microspheres of rabepazole sodium of various formulations is shown in table 3. When the floating microspheres of rabepazole sodium are dispersed in simulated gastric fluid without enzymes, owing to high water solubility, Eudragit RS 100 goes into solution forming pores on microspheres due to matrix erosion. This phenomenon leads the microspheres to float. From the results of floating efficiency we can conclude that floating microspheres prepared using Eudragit RS 100 and HPMC K4M showed good floating properties. However, as the ratio of HPMC K4M increased the floating behavior get reduced. This may be attributed to increased weight of microspheres. Parallel results were obtained with sitagliptin phosphate and metformin HCL.<sup>15,16</sup>

### ***IN-VITRO* RELEASE STUDIES**

The *in-vitro* release studies were conducted to investigate the effect of polymer Eudragit RS 100 and HPMC K4M on the release rate of floating microsphere of rabepazole sodium. The release of drug from a floating microspheres occur through diffusion mechanism due to drug polymer affinity that control the release of drug from the formulation. The *in-vitro* release of drug of different formulation are depicted in table 3 and graphically in fig.4. Maximum drug release rate (92.85%) was observed with formulation F6 having 50mg of HPMC K4M. It is evident from table 26 that as the concentration of HPMC K4M increase beyond 50mg, drug release rate decreases. This may be attributed to the increases in thickness of the outer surface of microspheres with increasing concentration of polymer HPMC K4M.

Table-3: In-vitro Drug release of floating microspheres of rabeprazole sodium of various formulations F1 to F4

| Time in hours | Cumulative percentage drug release |        |        |        |        |        |        |        |        |
|---------------|------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|
|               | F1                                 | F2     | F3     | F4     | F5     | F6     | F7     | F8     | F9     |
| 0             | 0                                  | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      |
| 0.08          | 7.981                              | 8.306  | 5.296  | 11.065 | 13.843 | 13.130 | 8.991  | 16.89  | 11.670 |
| 0.16          | 11.065                             | 12.067 | 17.428 | 17.229 | 26.586 | 20.165 | 13.130 | 23.5   | 16.342 |
| 0.33          | 17.358                             | 17.358 | 23.492 | 23.471 | 35.520 | 29.212 | 25.262 | 32.441 | 26.521 |
| 0.50          | 21.306                             | 23.047 | 28.342 | 26.471 | 44.383 | 38.188 | 31.820 | 38.167 | 31.880 |
| 0.75          | 25.488                             | 28.471 | 34.776 | 32.874 | 58.879 | 44.102 | 42.701 | 44.563 | 37.621 |
| 1             | 31.647                             | 33.532 | 40.679 | 40.174 | 65.954 | 50.853 | 53.489 | 50.038 | 44.335 |
| 2             | 36.524                             | 42.855 | 46.402 | 44.516 | 71.183 | 59.400 | 60.744 | 56.829 | 51.428 |
| 3             | 39.406                             | 53.093 | 52.933 | 55.879 | 77.401 | 66.835 | 69.315 | 62.674 | 56.599 |
| 4             | 43.855                             | 60.087 | 61.610 | 63.784 | 81.272 | 78.249 | 73.198 | 66.930 | 61.418 |
| 6             | 49.093                             | 65.784 | 65.685 | 70.749 | 86.746 | 83.904 | 77.058 | 74.791 | 68.644 |
| 8             | 58.530                             | 70.749 | 69.984 | 77.361 | 89.006 | 89.282 | 80.927 | 77.823 | 72.826 |
| 12            | 67.397                             | 75.361 | 77.385 | 85.803 | 90.321 | 92.853 | 87.474 | 83.761 | 80.567 |




Fig.4: Plot between cumulative % drug release vs time of F1 to F9 formulation

**Kinetic Analysis**

The release kinetics was found out by using zero order, first order, Higuchi, Peppas model. The results were shown in table 4. On the basis kinetic analysis it can be concluded that the drug release from the studied formulation followed Korsmeyer-peppas model as it has highest value of  $r^2$ . From the

table it has been observed that the regression value (n-value) of the formulation was 0.380 suggesting that the drug was released by fickian diffusion mechanism.

**Table-4: Parameters obtained from kinetic analysis of F6**

|                                |                          |       |
|--------------------------------|--------------------------|-------|
| <b>Zero order</b>              | <b>Slope (K)</b>         | 7.096 |
|                                | <b>Intercept</b>         | 30.83 |
|                                | <b>R<sup>2</sup></b>     | 0.735 |
| <b>First order</b>             | <b>Slope (K/2.303)</b>   | 0.039 |
|                                | <b>K</b>                 | 0.092 |
|                                | <b>Intercept</b>         | 1.830 |
|                                | <b>R<sup>2</sup></b>     | 0.950 |
| <b>Higuchi model</b>           | <b>Slope (K)</b>         | 27.29 |
|                                | <b>Intercept</b>         | 14.15 |
|                                | <b>R<sup>2</sup></b>     | 0.920 |
| <b>Koresmeyer peppas Model</b> | <b>Slope (n)</b>         | 0.380 |
|                                | <b>Intercept (log k)</b> | 0.212 |
|                                | <b>K</b>                 | 1.633 |
|                                | <b>R<sup>2</sup></b>     | 0.961 |

## CONCLUSION

In this investigation, Rabeprazole sodium floating microspheres with Eudragit RS 100 polymers were successfully prepared by the emulsion solvent diffusion method. Different percentage yield, particle size, percentage entrapment efficiency, and *in-vitro* floating efficiency were obtaining by varying the concentration of HPMC K4M in different formulations. *In-vitro* release studies showed that the drug is released from the formulation over period of 12h in a sustained manner & the release mechanism followed a fickian type. The release amount of Rabeprazole sodium from floating microspheres suggested that Rabeprazole sodium floating microspheres have potential to retain in stomach for sufficient long period and prolonging its duration of action of and bioavailability. In future *in-vivo* studies should be conducted so that such type of formulation of Rabeprazole sodium could find place in pharma market.

## **ACKNOWLEDGEMENT**

I take this privilege and pleasure to acknowledge the contribution of management of Lord Shiva College of Pharmacy, for providing excellent facility to carry out this work. We extend our thanks to Alkem laboratory Ltd. Mumbai for providing gift sample of Rabepazole sodium.

## **REFERENCES**

1. Chein Y.W. Novel drug delivery system, drug and pharmaceutical sciences second edition; 50: 139-141.
2. Ammi M, Krunal S, Hejal P, Yogi P. Advancements in controlled release gastroretentive drug delivery system: A review. *J Drug Delivery and Therap* 2012; 2(3): 12-21.
3. Khrwadkar P, Dashora K. Gastroretentive dosage forms: current development in novel system design and evaluation. *Amer J Pharamatech Res.* 2011; 1(3): 57-87.
4. Manmohan, Shukla TP, Mathur A, Upadhaya N, Sharma S. A review on gastroentive drug delivery system: an emerging approach to improve the gastric residence time of solid dosage forms. *Int J Pharma Sci Rev and Res.* 2011; 8(2): 176-182.
5. Rajkumar K, Goud RS, Sowjanya PS *et al.*, Floating microspheres: a novel approach in drug delivery. *J Drug Del Res.* 2012; 1(4): 1-20.
6. Gholap SB, Banarjee SK, Gaikwad DD, Jadhav SI, Thorat RM. Hollow microspheres: a review. *Int J Pharma Sci Rev and Res.* 2010; 1(1): 74-79.
7. Indian Pharmacopiea, The indian pharmacopiea commision, Ghaziabad; edition.2010; II (6): 2037-2038.
8. The Merck Index. An Encyclopedia of Chemicals, Drugs and Biologicals. Merck Research Laboratories; 14<sup>th</sup> edition.2006; 1209 -1392.
9. Somwanshi SB, Dolas RT, Nikam VK, Gaware VN, Kotade KB, Dhamak KB, Khadse AN. Floating multiparticulate oral sustained release drug delivery system. *J Chem and Pharma Res.* 2011; 3(1): 536-547
10. Lachman L, Lieberman, Kanig JL. The theory and Practice of industrial Pharmacy. Third edition, Varghese publishing house 1990; 67: 420-428,
11. Subrahmanyam CVS. Laboratory manual of physical pharmaceutics. 1st ed. Published by Vallabh Parkashan; 2002. 46-53.

12. Mane RB, Bhingre C, Bhalekar M. Preparation and Evaluation of carvedilol microsphere by spray drying technique: effect of process parameters on formulation. *Int J Pharma Quality Assur.* 2013; 4(1): 4-12.
13. Patel G, Tiwari A, Rabadia N. Floating microspheres as anovel tool for h2 receptor blocker. *Int Res J Pharm.* 2012; 3(2): 45-52.
14. Wagh DD, Mule MS, Jain DS. Gastroretentive floating microspheres: a review. *Int J Pharm and Tech.* 2011; 3(4): 1783-1799.
15. Wei Yu, Zhao L, Yu Y, Zheng W. Polymer blends used to prepare nifedipine loaded hollow microspheres for a floating type oral drug delivery system: *in-vitro* evaluation. *Arch Pharm Res* 2010; 33(3): 443-450.
16. Re MI, Biscans B. Preparation of microspheres of ketoprofen with acrylic polymers by a quasi-emulsion solvent diffusion method. *Powder Tech.* 1999; 101: 120-133.